Noxafil (Posaconazole) Patent Expiration, LOE Window & CMS Spending

Noxafil (Posaconazole) by Merck & Co.: FDA Orange Book LOE 2033-02-27, 14 AB generics, $4.0M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMerck & Co.
FDA Application & PathwayN022003 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2033-02-27
Orange Book Patents (*PED Extensions)6 patents (0 *PED)
Active AB-Rated Generic Competitors14
2024 CMS Total Public Spend$4.0M
2024 Medicare Part D Spend$632K
2024 Medicaid Spend$3.4M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.